2026-09-22
The 11th PCI Optimization by Physiology And Imaging (POPAI 2026) in Japan was a remarkable success. On 19th Sep, we were honored to host a dedicated Special Symposium: "Imaging-based Physiological Assessment of Coronary Artery Disease."
It's an honor for the PULSE Medical team to present our latest breakthroughs in anatomy-physiology-AI integrated PCI optimization solutions with a keynote presentation and two LIVE cases using μFR, AI-IVUS, UFR and co-registration solution.
Recently a new study by Tsunamoto et al. from Kobe University Graduate School of Medicine (Heart and Vessels, 2026) provides the first direct comparison of μFR and QFR against wire-based FFR in a real world chronic coronary syndrome cohort (82 vessels, 62 patients). The findings clearly favor μFR.
New data from the COMBINE OCT FFR trial (Elvin Kedhi, McGill University) show that an AI powered OCT vulnerability index – the Lipid to Cap Ratio (LCR) – can identify diabetic patients with non flow limiting lesions (FFR >0.80) who remain at substantially higher long term risk.
Dr. Simone Fezzi (University of Verona, Italy) presented a two?center study (150 patients, 158 vessels) evaluating the long?term physiological and biomechanical effects of magnesium resorbable scaffolds (MRS) – using Pulse Medical’s μFR and radial wall strain (RWS).
